tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Michael Ulz, 85 are a BUY (61.15%), 50 are a HOLD (35.97%), 4 are a SELL (2.88%).
Analyst Michael Ulz, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 57.05% that have a potential upside of 41.39% achieved within 171 days.
Michael Ulz’s has documented 307 price targets and ratings displayed on 34 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on YMAB, Y mAbs Therapeutics at 13-Aug-2024.
Analyst best performing recommendations are on NRIX (NURIX THERAPEUTICS ).
The best stock recommendation documented was for AKRO (AKERO THERAPEUTICS) at 12/19/2022. The price target of $40 was fulfilled within 1 day with a profit of $1.22 (3.15%) receiving and performance score of 31.46.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$205
$22.5 (12.33%)
3 years 4 months 11 days ago
3/5 (60%)
$35.09 (20.65%)
938
Hold
$173
$-9.5 (-5.21%)
$156
3 years 4 months 13 days ago
14/24 (58.33%)
$2.73 (1.60%)
682
Hold
$190
$7.5 (4.11%)
$194
3 years 7 months 12 days ago
9/11 (81.82%)
$34.41 (22.12%)
350
Hold
$166
$-16.5 (-9.04%)
$175
3 years 7 months 12 days ago
23/23 (100%)
$10.41 (6.69%)
828
Buy
$155
3 years 8 months 9 days ago
7/7 (100%)
$36.79 (31.12%)
395
Which stock is Michael Ulz is most bullish on?
Which stock is Michael Ulz is most reserved on?
What Year was the first public recommendation made by Michael Ulz?
